PB2330: PERIPHERAL T CELL LYMPHOMAS TREATED WITH SYSTEMIC CHEMOTHERAPY, CLINIC CHARACTERISTICS AND RESULTS AFTER TREATMENT: REAL LIFE STUDY IN A TERTIARY CARE HOSPITAL IN SPAIN
Authors: Daniel Garcia, Manuel Delgado, Nicanor Juan Rodríguez, Valentín Valdes, Guillermo Debén, Pio Torres, Rosario Varela, Rubén Vázquez, Victor Noriega
Journal: HemaSphere (2023)

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Peripheral T cell lymphomas (PTCLs) are a heterogeneous and uncommon group of lymphomas that comprise only between 10% and 15% of all non-Hodgkin lymphomas. Apart from some subtypes, PTCLs are aggressive in nature with rapid disease progression. Their prognosis is poor compared with that of patients with B-cell lymphomas, being still a therapeutic challenge. Aims: In this study, we aimed to analyze the outcome of patients diagnosed of PTCLs who have received systemic chemotherapy as one of their treatments. Methods: We have performed a descriptive retrospective analysis of 43 consecutive patients diagnosed of PTCL between 2012 and 2022 who had received systemic chemotherapy as one of their treatments. The survival analysis was performed with Kaplan-Meier curves and statistical significance was verified using the log-rank test, values of p<0.05 were accepted as statistically significant; all of it using SPSS 25.0 (IBM Corp., Armonk, NY, USA) Results: Median age was 67 (25-86) years, 55.8% (n=24) of the patients were older than 65 years old. PTCL subtype most frequently identified was PTCL not otherwise specified (30%, n=13), 77% (n=33) of patients had nodal disease, 30% (n=13) of them had bone-narrow involvement and 51% (n=22) of them had a high-intermediate or high International Prognosis Index (IPI). Anthracycline-based treatment regimens were the most frequent regimens used, mostly CHOP (57%, n=24). The overall response rate was 73% (n=28) with 58% (n=22) of complete remissions. Auto-HCT was performed on 23% (n=10), 80% (n=8) of them as first line consolidation treatment. Allo-SCT was performed on 9.3% (n=4), all of them on relapse. Brentuximab-vedotin was used as first line treatment on 5% (n=2), as second line treatment on 38.8% (n=7) and as third line treatment on 50% (n=7) of patients. With a median follow-up of 71 (14.9-150) months, 5-year overall survival and progression-free survival were 41% and 30% respectively, being their medians 25.8 and 20.2 months. Performing an auto-SCT, having a low IPI and being under 65 years old improved patient outcomes, being the 3 of them statistically significant (with p values of 0.004, 0.023 and 0.007, respectively). Summary/Conclusion: Regardless the limitations of a retrospective study, our results of patients diagnosed of PTCL have shown consistent data compared with results published in the literature, in terms of survival and response rates. Auto-SCT as first line consolidation treatment seems to be the best actual option. New T-cell lymphoma specific treatments, among which stands out Brentuximab-vedotin, have shown effectiveness. Their use combined with conventional chemotherapy may help achieve better response rates and therefore improve overall survival. Keywords: Peripheral T-cell lymphoma, T cell lymphoma, Lymphoma, Anaplastic large cell lymphoma